Faeth Therapeutics (FTH) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Faeth Therapeutics (FTH) has outperformed Vanda Pharmaceuticals (VNDA) over the past year, losing 9.6% versus a loss of 28.2%. Over five years, VNDA leads with a -79.2% price change compared with -95.0% for FTH. Vanda Pharmaceuticals is the larger company by market cap ($208.3 million vs $203.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FTH | VNDA |
|---|---|---|
| Share price | $7.88 | $3.45 |
| Market cap | $203.65M | $208.32M |
| 1-day change | -9.32% | -6.13% |
| YTD return | -26.15% | -60.94% |
| 1-year return | -9.64% | -28.23% |
| 5-year return | -94.96% | -79.18% |
| Forward P/E | — | 17.22 |
| EPS (TTM) | $-22.50 | $-4.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $216.10M |
| Revenue growth (YoY) | — | +8.72% |
| Net income (latest FY) | $-21.09M | $-220.47M |
| Gross margin | — | 93.96% |
| Operating margin | — | -69.95% |
| Net margin | — | -102.02% |
| 52-week high | $42.14 | $9.94 |
| 52-week low | $7.45 | $3.42 |
| Distance from 52-week high | -81.30% | -65.34% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +612.56% | +233.82% |
| Average volume | 500.25K | 1.06M |
| Shares outstanding | 25.84M | 60.47M |
| Employees | 29 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FTH has outperformed VNDA by 18.6 percentage points over the past year.
About Faeth Therapeutics
FTH stock →Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
FTH vs VNDA FAQ
Which is bigger, Faeth Therapeutics or Vanda Pharmaceuticals?
Vanda Pharmaceuticals (VNDA) is larger, with a market capitalization of $208.32M compared with $203.65M for Faeth Therapeutics (FTH).
Which stock has performed better over the past year, FTH or VNDA?
FTH returned -9.64% over the past 12 months, compared with -28.23% for VNDA (price return, excluding dividends). Past performance does not predict future results.
Are Faeth Therapeutics and Vanda Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.